Leap Therapeutics, Inc.
LPTX
$0.369
-$0.0053-1.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.89% | -11.71% | -5.37% | -6.82% | 7.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.64% | 28.54% | 46.19% | -65.66% | 12.72% |
| Operating Income | -8.64% | -28.54% | -46.19% | 65.66% | -12.72% |
| Income Before Tax | -24.78% | -27.54% | -52.07% | 66.99% | -4.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.79% | -32.71% | -52.07% | 66.99% | -3.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.79% | -32.71% | -52.07% | 66.99% | -3.00% |
| EBIT | -8.64% | -28.54% | -46.19% | 65.66% | -12.72% |
| EBITDA | -8.67% | -28.57% | -46.23% | 65.67% | -12.72% |
| EPS Basic | 17.80% | 13.08% | 42.81% | 84.19% | 56.78% |
| Normalized Basic EPS | -63.21% | 16.49% | 43.47% | 84.20% | 56.24% |
| EPS Diluted | 17.80% | 13.08% | 42.81% | 84.19% | 56.78% |
| Normalized Diluted EPS | -63.21% | 16.49% | 43.47% | 84.20% | 56.24% |
| Average Basic Shares Outstanding | 52.86% | 52.70% | 165.95% | 108.85% | 138.32% |
| Average Diluted Shares Outstanding | 52.86% | 52.70% | 165.95% | 108.85% | 138.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |